Clinical Trial Detail

NCT ID NCT03742102
Title A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer. (BEGONIA)
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors AstraZeneca
Indications

triple-receptor negative breast cancer

Therapies

Durvalumab + Oleclumab + Paclitaxel

Durvalumab + Paclitaxel + Selumetinib

AZD9150 + Durvalumab + Paclitaxel

Durvalumab + Paclitaxel

Capivasertib + Durvalumab + Paclitaxel

Age Groups: adult senior

No variant requirements are available.